Medical information Clinical review pending

Genetic Testing

TPP1 Gene Spinocerebellar Ataxia Type 7 Autosomal Recessive Genetic Test

Genetic test for mutations in the TPP1 gene associated with Spinocerebellar Ataxia Type 7 (SCA7), a hereditary neurological disorder. Utilizes Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (typically 5-10ml in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results: Confirm with the laboratory before booking.
Preparation: No special preparation is typically required for a blood draw. However, confirm with the laboratory for any specific instructions.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the TPP1 Gene Spinocerebellar Ataxia Type 7 Autosomal Recessive Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Individuals with symptoms suggestive of Spinocerebellar Ataxia (e.g., progressive ataxia, dysarthria, ophthalmoplegia).
✓Individuals with a family history of Spinocerebellar Ataxia Type 7.
✓Carrier screening in families with a known history of SCA7.
✓Prenatal diagnosis in families with a known TPP1 mutation.
✓Confirmation of diagnosis in suspected cases.

In plain language

What this test helps you understand

This test identifies mutations in the TPP1 gene, confirming a diagnosis of Spinocerebellar Ataxia Type 7 (SCA7). It aids in understanding the genetic basis of the condition within a family, facilitating genetic counseling and informed decision-making regarding family planning and potential management strategies.

The TPP1 Gene Spinocerebellar Ataxia Type 7 Autosomal Recessive NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to Spinocerebellar Ataxia Type 7 (SCA7). This hereditary neurological disorder affects the nervous system. The test uses Next-Generation Sequencing (NGS) technology for a detailed analysis of the TPP1 gene. This gene is important for the development and function of the nervous system. The test detects specific mutations in the TPP1 gene associated with SCA7. Analyzing DNA helps healthcare providers diagnose the condition and plan management strategies. Individuals with a family history of Spinocerebellar Ataxia or symptoms like loss of coordination, speech difficulties, vision problems, or muscle weakness may benefit from this test. Consulting a neurologist or genetic counselor can help determine if testing is appropriate. Early diagnosis can lead to informed family planning, tailored treatment plans, and better management options. A genetic counseling session is recommended to interpret results and discuss implications.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is typically required for a blood draw. However, confirm with the laboratory for any specific instructions.

SampleBlood sample (typically 5-10ml in an EDTA tube). Confirm specific requirements with the laboratory before booking.

MethodologyNext-Generation Sequencing (NGS) is used to analyze the TPP1 gene for pathogenic variants.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the TPP1 gene. It does not detect mutations in other genes that may cause similar symptoms. A negative result does not completely rule out SCA7 or other forms of ataxia. Results should be interpreted in conjunction with clinical findings and family history.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

SCA7 is a rare, inherited neurological disorder that causes progressive problems with movement, coordination, speech, and eye movements.

Individuals experiencing symptoms of SCA7 or those with a family history of the condition should discuss testing with their doctor or a genetic counselor.

A positive result indicates the presence of a mutation in the TPP1 gene associated with SCA7. It is important to discuss the implications with a healthcare provider or genetic counselor.

A negative result means no mutations were detected in the TPP1 gene. However, it does not completely rule out SCA7, as other genetic causes might exist. Discuss the result with your doctor.

Yes, genetic counseling is highly recommended before and after testing to understand the test, interpret results, and discuss implications for the individual and family.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp